TuHURA Biosciences Receives New U.S. Patent Broadening Coverage for its VISTA Inhibitor, TBS-2025
Patent extends coverage to include bispecific/multi-specific antibodies across all classes of human antibodies TAMPA, Fla., Oct. 13, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to...
Covered in this story
Call it yourself
No calls on $HURA yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Tuhura Biosciences Inc →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.